A carregar...
PHASE I-II TRIAL OF IMATINIB MESYLATE (GLEEVEC; STI571) IN TREATMENT OF RECURRENT OLIGODENDROGLIOMA AND MIXED OLIGOASTROCYTOMA. NORTH CENTRAL CANCER TREATMENT GROUP STUDY N0272 (ALLIANCE/NCCTG)
PURPOSE: To evaluate the pharmacokinetics and efficacy of imatinib in patients with recurrent oligodendroglial tumors. METHODS: Patients with progressive WHO grade II-III recurrent tumors after prior RT and chemotherapy were eligible. A phase I dose-escalation study was conducted for patients on enz...
Na minha lista:
| Publicado no: | J Neurooncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717651/ https://ncbi.nlm.nih.gov/pubmed/31119479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-019-03194-z |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|